THE ANALYSIS OF PIG GENE CLUSTER EXPRESSION IN THE LUNG CANCER

猪基因簇在肺癌中的表达分析

• 批准号: 11670593
• 负责人: SATO Tetsuo
• 金额: $ 1.92万
• 依托单位: JIKEI UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11670593/
• 关键词: PIG; P53; lung cancer

The lung cancer is a disease of poor prognosis, which shows the resistance for the treatment. The change of expression of p53 induced gene (PIG) as one of the causes of this refractory. In this study, it is made that lung cancer gene therapy that it clarified the change of the expression of the PIG gene cluster and gave in the beginning develops further to be a purpose. The tissue of the lung cancer collected via bronchoscope or operatively is cultured in 10%FCS RPMI with anti-cancer drugs such as CDDP, BLM and Pacritaxel for some periods. And examine whether p53 gene cluster is activated or not. The gene therapy, which introduced p53 into lung cancer of the patient by Adeno virus, was started in December, last year in our hospital. Description and agreement document to the patient were also being made. When this clinical research was started, the permission of the ethics committee was also obtained. Only few patients were proved the p53 gene abnormality in our institute until now. It is less than the frequency by the report ever since (about 50%). 51-year old man who suffered with lung carcinoma was given CDDP and Ad5CMV-p53. But he refused further any anti-cancer treatment, therefore the formal evaluation about tumor reduction effect was impossible. But the temporary tumor reduction effect was observed and his performance status did not change.On the analysis of the PIG gene, many patients must be included. In future, we will do further effort.

肺癌是一种预后不良的疾病，表现出对治疗的抵抗力。 p53诱导基因(PIG)表达的改变是造成这种难治性的原因之一。本研究以阐明PIG基因簇的表达变化为目的，提出了进一步发展肺癌基因治疗的目的。将经支气管镜或手术采集的肺癌组织在含CDDP、BLM、紫杉醇等抗癌药物的10%FCS RPMI中培养一段时间。并检测p53基因簇是否被激活。我院从去年12月开始，通过腺病毒将p53导入患者的肺癌中进行基因治疗。还正在向患者提供描述和协议文件。这项临床研究开始时，也获得了伦理委员会的许可。迄今为止，我院仅有极少数患者被证实p53基因异常。低于此后报告的频率（约 50%）。 51 岁患有肺癌的男性接受了 CDDP 和 Ad5CMV-p53 治疗。但他拒绝进一步进行任何抗癌治疗，因此无法对肿瘤缩小效果进行正式评估。但观察到了暂时的肿瘤缩小效果，并且他的体能状态没有改变。在PIG基因的分析上，必须包括许多患者。未来，我们将更加努力。